Haemonetics Sets Date for Publishing First Quarter Fiscal Year 2027 Results: August 6, 2026
Rhea-AI Summary
Haemonetics (NYSE: HAE) will publish first quarter fiscal year 2027 financial results at 6:00 a.m. ET on Thursday, August 6, 2026. A conference call for investors and analysts follows at 8:00 a.m. ET, with live webcast and one-year replay available via the investor relations website.
Positive
- None.
Negative
- None.
News Market Reaction – HAE
In the Jul 9 session, HAE gained 1.60%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Previous Earnings date Reports
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| Apr 01 | Earnings date notice | Neutral | +1.1% | Set reporting date and call time for Q4 and FY26 results. |
| Jan 07 | Earnings date notice | Neutral | +1.3% | Announced Q3 FY26 results release timing and investor call details. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Similar earnings-date notices have coincided with modestly positive one-day moves on past announcements.
AI-generated analysis. How Rhea-AI works. Not financial advice.
The call can be accessed via teleconference at: Q1 2027 Haemonetics Corporation Earnings Conference Call. Once registration is completed, participants will receive a dial-in number along with a personalized PIN to access the call. While not required, it is recommended that participants join 10 minutes prior to the event start.
A live webcast of the call can be accessed on Haemonetics' investor relations website. Webcast Link: https://edge.media-server.com/mmc/p/r8e9tnfy
A replay of the conference call and webcast will be available for one year beginning on August 6, 2026 at 11:00 am ET using the conference call webcast link provided in this press release.
ABOUT HAEMONETICS
Haemonetics is a global medical technology company dedicated to improving the quality, effectiveness and efficiency of health care. Our Apheresis business features proprietary technologies designed to enhance safety, yield, donor satisfaction and operational efficiency for plasma and blood collectors around the world. Our MedSurg business offers Blood Management Technologies to help inform treatment decisions and optimize the management of blood products, and Interventional Technologies, including advanced vascular closure systems and sensor-guided technologies, designed to drive procedural effectiveness and elevate the patient experience. To learn more about Haemonetics, visit www.haemonetics.com.
Investor Contacts | |
Olga Guyette, VP - Investor Relations & Treasury | David Trenk, Senior Manager - Investor Relations |
(781) 356-9763 | (203) 733-4987 |
|
|
Media Contact | |
Josh Gitelson, Senior Director - Global Communications | |
(781) 356-9776 | |

View original content to download multimedia:https://www.prnewswire.com/news-releases/haemonetics-sets-date-for-publishing-first-quarter-fiscal-year-2027-results-august-6-2026-302821033.html
SOURCE Haemonetics Corporation